We are live on
!
Find out more
Puma Biotechnology
PBYI
PBYI
203 hedge funds and large institutions have $3.59B invested in Puma Biotechnology in 2017 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 76 increasing their positions, 56 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
165% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 20
36% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 56
19% more funds holding
Funds holding: 171 → 203 (+32)
7% less call options, than puts
Call options by funds: $72.5M | Put options by funds: $77.8M
2.13% less ownership
Funds ownership: 98.59% → 96.46% (-2.1%)
18% less capital invested
Capital invested by funds: $4.39B → $3.59B (-$804M)
50% less funds holding in top 10
Funds holding in top 10: 12 → 6 (-6)
Holders
203
Holders Change
+32
Holders Change %
+18.71%
% of All Funds
4.6%
Holding in Top 10
6
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-50%
% of All Funds
0.14%
New
53
Increased
76
Reduced
56
Closed
20
Calls
$72.5M
Puts
$77.8M
Net Calls
-$5.32M
Net Calls Change
-$18.5M
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$276M |
| 2 |
D.E. Shaw & Co
New York
|
+$96M |
| 3 |
BlackRock
New York
|
+$63.8M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$52.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$50.6M |
